Summary
This prediction ended on 13.02.12 with a price of €2.65. The BUY prediction by Haans for Evotec SE saw massive gains of 39.73%. Haans has 50% into this predictionEvotec is a German-based biotech company that provides drug discovery and development solutions to pharmaceutical and biotechnology companies. The company operates in the fields of neuroscience, immunology, oncology, and infectious diseases, and its services include hit identification, target validation, and preclinical and clinical development. Evotec has partnerships with major pharmaceutical companies and has developed its own pipeline of drugs, with a focus on developing treatments for conditions such as Alzheimer's disease and diabetes. The company is listed on the Frankfurt and NASDAQ stock exchanges and has a market capitalization of approximately €5.5 billion.
Performance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Evotec SE | -2.299% | -2.299% | -49.189% | -71.749% |
| iShares Core DAX® | 4.094% | 3.543% | 17.404% | 20.326% |
| iShares Nasdaq 100 | 1.424% | 0.512% | 39.212% | 55.365% |
| iShares Nikkei 225® | -1.572% | -4.633% | 15.731% | 2.146% |
| iShares S&P 500 | 1.822% | 0.963% | 30.396% | 45.950% |
Comments by Haans for this prediction
In the thread Evotec AG diskutieren
Buy on good news
Evotec erhöht Ausblick für laufendes Geschäftsjahr - Schwarze Zahlen
Evotec ereicht bald den Wiederstand bei etwa 2 Euro. Nach überwinden des Wiederstandes ist der Weg bis etwa 3,10 frei. Danach kann ich mir auch noch höhere Kurse vorstellen, aber .....